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 We live in a world of ever-increasing knowledge and dissemination of data. This 
information can provide us with new concepts or associations which may hold significant 
implications for how we approach problems. However, we must be cautious in how we appraise 
such information. There are circumstances in which tenuous epistemologic linkages or hints of 
burgeoning concepts lead to heavy overestimation in our deliberations and actions, which may 
negatively impact the ways in which individuals behave and policymakers legislate. It is 
therefore becoming increasingly important to take account of how we ought to evaluate new 
information. We must derive a structured, systematic approach to how we weigh different forms 
and levels of evidence within our deliberative processes. In the face of radical uncertainty and 
shaky epistemologic foundations, there manifests ethical responsibilities with two normative 
claims: ethically responsible deliberation and ethical action in response to the deliberation. This 
thesis offers a novel framework for the ethical evaluation of evidence in decision-making based 
upon an appraisal of the strength of evidence and magnitude of impact of a given situation – the 
Evidence Appraisal & Actionability Tool. The tool further purports an ethical actionability 
depending upon the grade. One example of its application to a newly forming scientific concept 
– the potential interactions between the gut microbiome, livestock, and human obesity – 
illustrates its utility and interpretation. Ultimately, the value offered by this Evidence Appraisal 
& Actionability Tool is in its ability to provide guidance for how one ought to incorporate 
existing information into one’s decision-making in an ethically appropriate fashion, regardless of 
context or circumstance, and how one ought to act in response to such evidence. 
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 We live in a world of ever-increasing knowledge and dissemination of data. This 
information can provide us with new concepts or associations which may hold significant 
implications for how we approach problems. However, we must be cautious in how we appraise 
such information. There are circumstances in which tenuous epistemologic linkages or hints of 
burgeoning concepts lead to heavy overestimation in our deliberations and actions, which may 
negatively impact the ways in which individuals behave and policymakers legislate. It is 
therefore becoming increasingly important to take account of how we ought to evaluate new 
information. 
We must derive a structured, systematic approach towards how we weigh different forms 
and levels of evidence within our deliberative process. In the face of radical uncertainty and 
shaky epistemologic foundations, there manifests ethical responsibilities in how we approach and 
weigh information, the ethical implications between the deliberative and action processes, and in 
the consequences yielded from the actions taken based upon the deliberations. It implies both an 
ethics of process as well as consequence. Thus, there are two normative claims: ethically 
responsible deliberation and ethical action in response to the deliberation. This thesis offers a 
novel framework for the evaluation of evidence in ethical decision-making based upon an 
appraisal of the strength of evidence and magnitude of impact of a given situation. It then 
provides an example of its application to a newly forming scientific concept – the potential 
interactions between the gut microbiome, livestock, and human obesity. Ultimately, the value 
offered by this Evidence Appraisal & Actionability Tool is in its ability to provide guidance for 





appropriate fashion, regardless of context or circumstance, and how one ought to act in response 
to such evidence. 
 
II. Background 
 There is uncertainty underlying the data that informs our decisions. One can posit that a 
person can never be 100 percent certain that the action they perform will result in its intended 
consequence. This is an idea David Hume discusses in his concepts of “relations of ideas” and 
“matters of fact” in An Enquiry into Human Understanding (Hume, 1779). “Relations of ideas” 
concern topics such as logic and mathematics where the premises and conclusions are 
objectively demonstrable, 100 percent predictable, and proven by reason a priori. An example of 
this is the proposal that the angles of a Euclidean triangle will always sum to 180 degrees. This is 
knowledge that remains true regardless of whether it is found in nature. This is in contrast to 
“matters of fact,” which he defines as forms of knowledge relying upon cause and effect 
relationships determined through experience and induction. As such, the process of inductive 
inferences from previous observations of cause and effect implies that there always remains a 
possibility of a resulting expected effect being expectation-dystonic from the observed cause. For 
example, one could drop a pencil with the expectation of it hitting the ground. One has witnessed 
the cause-effect relationship between dropping objects and gravity thousands of times in the past, 
so one has near 100 percent certainty this will be the result again. Yet it is possible that a stray 
ripple through spacetime could force its way through the expected dropped pencil’s path to 
propel it towards the ceiling. This may be an extreme example but is intended to illustrate the 
idea that even in circumstances in which we have a tremendous amount of certainty in the data 





extreme end of uncertainty, we can point out that all empirical claims are uncertain; yet there are 
certainly relative differences in degrees of uncertainty, so we must decide when that uncertainty 
impedes action. 
This concept of ambiguity surrounding the data informing our decisions is particularly 
important in cases of radical uncertainty. What do we mean when we say “radical uncertainty”? 
It is the phenomenon in which there is a considerable amount of ambiguity or lack of solid 
clarity regarding the evidence for a situation. Yet, practically speaking, it is the case that 
regardless of the level of certainty of the data we have before us, we must act with what existing 
evidence we have. For example, there may hypothetically be a new study released demonstrating 
a potential association between cat ownership and pancreatic cancer. However, there may only 
be only a small handful of studies even considering this issue with a great deal of uncertainty 
regarding the accuracy of the claim. Regardless, we must decide how we ought to approach this 
potential issue of cats and pancreatic cancer from a public health perspective. Shall we make a 
uniform policy banning cats from households? Will we relay public warnings of the dangers of 
cats and cancer? Or should we not act upon this data? 
In this example, it seems obvious the correct approach would be to give very little weight 
to these proposed associations and appropriately decide not to act upon this tenuous evidence. 
However, this is not always the case. We could replace cat ownership with any myriad of 
potential exposures (e.g. sugar consumption), and it could elicit a more distressing issue of 
radical uncertainty. It is therefore also important to determine what the obligation to action is in 
response to newfound information with respect to research, behavior, policy, etc. It would be 
inappropriate to invest time and resources into a highly suspect idea (e.g. cat exposure and 





presented concepts which are more plausible with similar levels of evidential uncertainty that 
may warrant further investigation (e.g. sugar consumption and pancreatic cancer). Thus, there 
appears to be a difference between credible radical uncertainty and implausible radical 
uncertainty. 
It is important to also differentiate radical uncertainty from speculative ethics, which 
examines ethical concerns that arise from hypothetical future contexts (Schick, 2016). For 
example, a speculative concern might address the potential for future nanotechnologies to wipe 
out an entire species and discuss the ethics of how we ought to approach nanotechnology both 
now and in the future. This is also to differentiate radical uncertainty from general uncertainty, in 
which ethical ideas such as decision theory, utilitarianism, and the precautionary principle come 
into play. Radical uncertainty must be considered as a distinct concept and one which holds 
increasingly greater importance in our world. 
 How we weigh and consider the data and information available to us is necessarily an 
ethical pursuit. When attempting to act on the basis of evidence, we weigh the evidence available 
to us and choose the path that we judge most likely, based on the evidence, to bring about the 
desired outcome. How we make decisions and take actions with ethical impacts – whether 
because it brings about harms or benefits, leads to rights violations or injustice, etc. – is 
necessarily an ethical pursuit. Thus, we have an ethical impetus to appropriately weigh data and 
information in our decision-making. 
 We live in a suboptimal data and evidence world. If we had knowledge of all of the 
causal factors underlying consequences or natural manifestations we observe in addition to the 
exact cause-effect impacts of our actions, we would live an optimal evidence environment. 





require us to act either responsively or preemptively under varying degrees of uncertainty 
regarding the causes of the problems and the relationship between our actions and intended 
consequences. If one were to make decisions based upon shaky evidence, then one would be 
taking a risk. If those decisions held ethical impacts, then that decision-making process could be 
deemed ethically shaky from a consequences and/or process perspective. 
 One clear example of this comes from the world of preventive medicine and public health 
through the United States Preventive Services Task Force (USPSTF) recommendations. The 
USPSTF’s job is to offer standard of care recommendations for preventive interventions for all 
primary care providers based upon available evidence. For example, the USPSTF recommends 
that all women who are planning on or capable of becoming pregnant take daily folic acid 
supplementation to avoid potential neural tube defects in a developing fetus (USPSTF, 2017). 
They take a particularly scrutinizing eye to the existing data regarding a health care service and 
disease outcome to arrive at their judgments. Sometimes they change their recommendations 
based upon new studies that add more perspective to the literature. However, there are situations 
in which the evidence is still weak or new, yet they must still come to a decision as to how to 
value this information and what they will recommend based upon it. The USPSTF therefore 
developed a grading scheme for their recommendations and categorize them according to their 





Figure 1: USPSTF Recommendation Grades 
 
The USPSTF is therefore forced into the position where they must make decisions that 
may have substantial health and ethical impacts on millions of patients but where there is 
considerable uncertainty underlying the data on which they base their recommendations. For the 
USPSTF, an “I” grade constitutes radical uncertainty in that the potential screening or prevention 
modality is credible enough to be worth assessing, yet there is an insufficient level of confidence 
regarding the harms and benefits. Since their recommendations impact millions of patients and 
are geared towards preventive measures, their threshold for certainty and confidence in the data 
is much higher than might be considered in other contexts. Thus, they neither recommend nor 
recommend against the practice in question if it is judged to be grade “I”. They instead leave it to 
the discretion of the provider with the stipulation they convey the uncertainty of the data to the 
patient. Further, they do not provide guidance or actionability regarding the next steps related to 





 How we ought to approach data increases in difficulty under conditions of radical 
uncertainty. Considerable levels of uncertainty leave us much less confident in how we should 
proceed, and we must think through this process. We are confronted by an ever-growing front of 
new pieces of information and associative linkages which must be accounted for in our 
deliberations. Yet there is not an existing evidence appraisal method which links ethical 
obligations and actionability. Therefore, we require a framework for thinking about radical 
uncertainty and how we weigh various levels of information confidence into our ethical decision-
making. Further, we need a method for determining what level of uncertainty we currently are in 
for a given subject, and what ethical responsibility we have in how we ought to weigh that 
information in light of that determined level. 
 
III. An Approach to the Consideration of Information 
 There are two appraisal components to the Evidence Appraisal & Actionability Tool: 
strength of evidence and magnitude of impact. First, we must make an assessment regarding the 
strength of evidence. This represents the level of certainty we have regarding the information at 
hand. There are several conceptual measures which contribute to this criterion. One grouping of 
concepts is Hill’s criteria for causality, which includes a set of nine areas that contribute to an 
epidemiologic conclusion for a causal relationship between a cause and effect. It includes 
strength, reproducibility, specificity, temporality, biological gradient, plausibility, coherence, 
experimental evidence, and analogy (Hill, 1965). Though some of these concepts do not apply to 
every context (e.g. biological gradient), they provide a useful guide in asserting which criteria we 
ought to value in considering our strength of evidence. One may also turn to other existing 





validity, generalizability), etc. for more input into guiding how one ought to frame data and 
information. The key ideas inherent to the strength of evidence component include our level of 
confidence in the data presented to us, which relies upon other underlying concepts such as 
quality and trustworthiness of the research. Once we have assessed the available information per 
these values for strength of evidence, we must then categorize it as Strong, Moderate, or Weak. 
 After we have completed this first step, we must then consider the magnitude of impact. 
The conceptual measures for the magnitude of impact may vary depending upon which context 
one is applying the tool. However, for a public health-based consideration, potential concepts 
might include morbidity, mortality, quality of life, economic impact, etc. One must consider 
various distributions of impact as well, as they may be equivalent in different ways – e.g. an 
enormous impact on a small number of people vs a small impact in a large number of people 
might both be categorized similarly. The idea underlying the magnitude of impact component is 
that we must consider the entire scope of magnitude and effects incurred by the information 
being appraised. Once it has been assessed, we must then categorize it as Substantial, Moderate, 
or Minimal. 
 Upon full assessment and consideration of the strength of evidence and magnitude of 
impact, one must then categorize the data utilizing the Evidence Appraisal & Actionability Tool, 





Figure 2: The Evidence Appraisal & Actionability Tool 
 
The Evidence Appraisal & Actionability Tool provides grades for the data one is assessing based 
upon these measures of evidence and impact. Its value is derived from its ability to provide 
guidance concerning the ethical responsibilities of how one ought to proceed regarding their 
decision-making in light of available information and approaching such data. The guidance 
varies depending upon its grading categorization and yields the following conclusions: 
Grading: 
• A = One must incorporate this data in deliberations and consider it trustworthy. 
• B = One ought to strongly consider this data in deliberations and consider it trustworthy. 
• C = This data ought to be considered on a case-by-case basis. 
• Weak Evidence, Substantial Magnitude (C1): One should approach the data 
cautiously and be careful of the amount of weight placed on its results. More 
research is required to trust the data with greater confidence and more accurately 
discern its impact. Because it has the potential for a substantial magnitude of 





• Strong Evidence, Minimal Magnitude (C2): One should trust the data, but one 
should not heavily weigh it in deliberations. It may act as a contributing feature 
but should not lead the main discussion. 
• D = There may be relevant concerns in this data, but it ought not to be considered in most 
cases. More research is required to accurately discern its impact with greater certainty. 
• F = This data is insignificant and poorly formed; it should not be considered at all in 
deliberations. 
There are some further considerations relevant to the use of the tool. First, it is important 
to clearly differentiate the Evidence Appraisal & Actionability Tool from other data evaluation 
tools, such as the USPSTF recommendation grades. There are differences in judgment kinds 
regarding who is undertaking the decision-making. For example, there is a significant difference 
in considering “C1” level data on nationwide policy decisions versus those made by individuals. 
It would be unethical and irresponsible in the vast majority of cases for one to seriously weigh 
and act upon C1 level data impacting thousands to millions of people. This is a weighty 
consideration for the USPSTF when providing guidance regarding preventive recommendations 
at a national level. Thus, they only make affirmative “a provider should offer this service” 
recommendations when there is a significant amount of evidence to support their decision. On 
the other hand, if an individual wanted to act upon C1 level data that impacted only him- or 
herself, it may be more justifiable to do so. One might ask, “Why doesn’t the Evidence Appraisal 
& Actionability Tool look like USPSTF’s or any other decision matrix (e.g. American College of 
Cardiology/American Heart Association)?” These matrices serve very particular contexts. For 
example, the USPSTF must specifically determine which preventive services are appropriate and 





decision matrix is incredibly conservative. The ACC/AHA must offer recommendations 
regarding treatment modalities and procedures physicians consider at the individual physician-
patient level (ACC/AHA Task Force on Practice Guidelines, 2010; Halperin, et al, 2015). Their 
recommendations are more flexible regarding the assessment of evidence and what is considered 
sufficient for different levels of claims as to how physicians should act in response to such 
evidence. However, the Evidence Appraisal & Actionability Tool is not constrained to the public 
health or physician-patient dyad contexts – it may be applied across any discipline. 
These other decision tools such as USPSTF’s and ACC/AHA’s are certainly useful, yet 
they are not designed to provide normative obligations or offer epistemologic guidance across 
disparate contexts. There are examples where epistemology is invoked in the ethical debate 
regarding how we ought to appraise data and what obligations we have to our actions and 
decision-making process based upon that data. Two prominent examples of this are climate 
change and vaccines. In both of these situations, they both have substantial magnitude of impact 
and there are very convincing data supporting its existence, and safety and efficacy, respectively. 
Thus, one can determine via the Evidence Appraisal & Actionability Tool that they would both 
be A grades - one must incorporate this data in deliberations and consider it trustworthy. 
However, there remain those who do not harmonize their decision-making processes and related 
actions with the existing evidence base for these concepts. As such, based upon the Evidence 
Appraisal & Actionability Tool, we may determine that those who reject the evidence supporting 
climate change and vaccines are acting unethically by being epistemologically irresponsible, 
which leads to dangerous, unethical consequences (e.g. not promoting environmentally 
supportive legislation; not vaccinating one’s children despite lack of contraindications). Further, 





utilize the evidence in their decision-making and actions are also acting unethically. Therefore, 
the frameworks are similar in that they all concern the appraisal of data and information. 
However, they are distinctly different in that only the Evidence Appraisal & Actionability Tool 
offers normative weight in how one ought to act or is even ethically obligated to act in the face 
of certain grades of evidence. 
Second, the grading is not static; it is a dynamic process. For example, an area of data can 
move from D to C to B to D (or what have you) as more research and information is gained on 
the subject. Knowledge assurance and our consideration of it is dynamic; it is influenced as we 
learn more about the subject. 
Third, how one considers the grading may depend upon the context due to judgments of 
different kinds. One criticism of the tool might argue that the demarcations between the levels 
for the strength of evidence and magnitude of impact are too vague and allows too much room 
for disagreement regarding categorization. Though this is certainly a concern, the tool must be 
flexible enough to apply across a variety of decision-making contexts. For example, there are 
different standards for evidence in engineering fields compared to social sciences. This tool 
could help different fields to individually determine how they wish to weigh their information 
via a deliberative process, though the values and gradings remain constant across disciplines. 
Fourth, there is no category for when data reveals negligible or no effect. Though it might 
go without saying, all data of this type should be categorized with an “F” grade. One should not 
weigh it at all in decision-making. Similarly, if the evidence is so untenable or implausible to the 
extent a possibility of its veracity is remote, it should also be categorized with an “F” grade. 
Therefore, one can imagine a surrounding border of red “F” grades below minimal magnitude of 





Fifth, not all evidence contexts within the same grading categorization are equal. For 
example, two separate contexts could both considered grade C2 yet have differences between 
them. One can imagine the C2 box as a two-dimensional sliding scale with differing levels of 
strength of evidence and magnitude of impact even within this category. This is demonstrated 
graphically with the two hypothetical contexts labelled “1” and “2” as follows: 
Figure 3: Example of the Two-Dimensional Sliding Scale within the Evidence Appraisal & 
   Actionability Tool 
 
 
Context 1 illustrates a situation in which we are very confident in the evidence and there is only a 
minimal potential impact of the decision, action, or evidence. As such, context 1 is assuredly a 
C2. Yet Context 2 lies on the edge of three other categories: Strong-Moderate B, Moderate-
Moderate B, and Moderate-Minimal D. Its position could quickly slide from the C2 category to 
B or D depending upon what future evidence is presented. Thus, even within each category, each 
context is different and nuanced. However, the ethical responsibility and guidance concerning 
that information remains the same regardless of the intra-category variation. 
 Sixth, the discussion of intra-category variation raises the question of why Moderate-
Moderate, Strong-Moderate, and Moderate-Substantial categories are all considered Grade B 
recommendations. The reasoning remains the same. Although these three categories contain 





equivalent. Namely, although they may demonstrate these differences in character, they all 
warrant strong consideration in deliberations and should be considered trustworthy. 
 There is one final caveat to this as well, and it regards emergency circumstances. There 
may arise dire cases in which one absolutely must act in some way despite little or no evidence to 
substantiate one’s expected action-consequence connection. Some examples might include a 
global response to an impending meteor impact of catastrophic magnitude, an individual’s 
countermeasures to stave off a much more powerful malcontent, etc. Yet in each of these 
circumstances, the basic underlying theme remains the same – even if there is possibly little to 
no evidence to support one’s decisions in a must-act situation, one must still apply the same 
reasoning in the tool (i.e. weighing certainty and magnitude of impact) if one wishes to act 
responsibly and ethically. 
In summary, uncertainty often underlies the data and information we receive. However, 
we must nevertheless make decisions and act while relying upon varying types and degrees of 
uncertainty of data. These decisions and actions have ethical implications for both the user and 
on those they may impact. We therefore have an ethical obligation to appraise such information 
in a responsible way. The Evidence Appraisal & Actionability Tool offers us a method by which 
to fulfill this ethical responsibility. Further, it provides guidance regarding how we ought to 
weigh relevant information according to each grade of evidence. The next step is to apply the 
tool to a case study which exemplifies its use in a context of evidential radical uncertainty. A 
prime example of this from a public health perspective is the potential association between 
human-livestock microbiome transmissibility and the subsequent development of obesity, i.e. the 






IV. The Hologenome and Human Obesity 
A. Introduction 
 Humans have been omnivorous from the time we diverged as our own species from the 
genetic tree. Since that time, we have created increasingly more efficient ways of cultivating 
animals for consumption to satiate our carnivorous desires. However, we have found through 
empirical evidence that meat consumption incurs a multitude of negative effects for human 
health, animal treatment, and environmental well-being. Yet despite knowledge of these negative 
consequences, most of the planet continues to increase its meat consumption at an alarming rate. 
In order to fulfill such market demands, livestock farmers and agricultural corporations over the 
past century have been artificially selecting for and breeding their cash animals to be more and 
more metabolically efficient. Such metabolic efficiency allows them to achieve several times 
larger yields for the same amount of resource input. However, by artificially selecting for more 
metabolically efficient animals, we may have been inadvertently pushing humanity towards 
becoming more metabolically efficient humans. The present section will investigate the ethics of 
livestock artificial selection in the context of the obesity epidemic and global climate change and 
will demonstrate the application of the Evidence Appraisal & Actionability Tool. 
B. The Hologenome, Livestock, and Obesity 
 Obesity is defined by the CDC as “weight that is higher than what is considered as a 
healthy weight for a given height,” and is multifactorial (CDC, 2016; Dhurandhar & Keith, 
2014). It is a rising epidemic in the United States and across the world. Per the CDC’s National 
Center for Health Statistics 2015-2016 data, 71% of adults over 20 years-old in the U.S. were 





prevalences compared to just 20 years ago (CDC, 2017). Obesity has grown across all spectrums 
of age, gender, and race. Since the 1960’s, not only has obesity tripled among adult populations, 
it has also nearly quadrupled in children and adolescents, as demonstrated by CDC data (Fryar, 
et al, 2018 [1]; Fryar, et al, 2018 [2]): 






Figure 5: CDC Data on Overweight, Obesity, and Severe Obesity in Children and Adolescents in 
the U.S. 
 
Obesity’s harmful health consequences are striking. It affects the body negatively in a 
wide variety of ways: it increases the risk of mortality, hypertension, hyperlipidemia, type 2 
diabetes, coronary heart disease, stroke, gallbladder disease, osteoarthritis, sleep apnea, some 
cancers, lower quality of life, depression, anxiety, and difficulty with physical functioning (CDC, 
2016). As is likely evident, this incurs a tremendous cost in terms of its economic impacts from 
direct and indirect costs. In 2008, the medical care costs of obesity in the United States was $147 
billion, and the annual nationwide productivity costs related to absenteeism secondary to obesity 
ranged from $3.38 billion to $6.38 billion (CDC, 2016). Obesity is therefore one of the most 





 Obesity epidemics are not just limited to humans. There appears to be a concurrent 
plurality of obesity epidemics across species and across the same timeframe, which has raised 
questions for some researchers about the potential connections between the two. One study 
analyzing historic weight records for 24 animal populations that interact with humans (including 
domesticated animals, rodents, and primates) have shown this same pattern of weight gain over 
the past century that cannot be explained by statistical chance alone (Klimentidis, et al, 2011). 
The symmetry of selection phenomena is important when considering a common thread between 
convergent phenotypes, as they can emerge independently in different species. One critical 
selection modality is the human element, as anthropogenic influence is now a salient component 
of many selection phenomena (Thompson, 2013; Whitham, et al, 2006). As such, there are a 
variety of anthropogenic mechanisms through which animal obesity may be influencing human 
obesity. What accounts for this phenotype diffusion across species? One explanation is that this 
plurality of obesity across species may be reflective of a shared vulnerability such as 
constitutional or genetic changes within gut microbiomes. 
 The human gut microbiota consists of the trillions of symbiotic microorganisms harbored 
by an individual, including bacteria, viruses, eukaryotic microbes, and archaea (Shreiner, et al, 
2016). The gut microbiome refers to the collective genomes within these microorganisms 
(Turnbaugh, et al, 2007). They contribute metabolic functions, inform our immune systems, and 
protect against other pathogens (Shreiner, et al, 2016). The hologenome is a construct which 
considers a host organism and all of its associated symbiotic microbiota (e.g. flora of the gut, 
skin, mouth, pulmonary tree, genitourinary tracts, etc.) as a single unit. The human genome is 
comprised of around 23,000 genes and a human microbiome encodes about 3,000,000 genes, 





2016). A complex symbiosis between a human body and its microbiome exists, and if this 
interaction becomes disrupted, it can have detrimental, pathologic effects on both (Scotti, et al, 
2017). Studies have demonstrated that dysbiosis (microbial imbalance) between humans and 
their gut microbiome can hold significant pathologic health impacts in terms of risk of obesity, 
certain diseases, and even mental health (Scotti, et al, 2017): 
Figure 6: Diseases Linked to the Microbiome 
 
In general, microbiota diversity is an approximate surrogate for the health of a microbiome, and 
lower diversity is considered a marker for dysbiosis (Valdes, 2018). However, we are finding 





health in specific ways. Further, the bacteria which comprise the gut microbiome have been 
shown to be transferrable not only from person-to-person but also zoonotically, lending credence 
to taking a One Health perspective regarding gut microbiota (Xiao, et al, 2016; Song, et al, 
2013). 
 Over the past 150 years, humans have been artificially selecting many livestock for their 
metabolic phenotype (i.e. obesity), such as cattle and chickens (Bovine HapMap Consortium, et 
al, 2009; Zuidhof, et al, 2014). A chicken breed that was commercialized in 1957 and another 
breed from 2005 were recently raised under the same conditions with the same food, and the 
2005 breed weighed four times more than the 1957 breed (Zuidhof, et al, 2014). By selecting for 
obesity in these livestock animals, we may have also been inadvertently selecting for gut 
microbiota that are obesogenic. Similar to plants and their relationship to soil, artificial selection 
of the gut microbiome can act on animals on short timescales (e.g. lifetimes), and is supported by 
experimental evidence in pigs, rats, and voles (Lyte, et al, 2016). We also have human twin and 
metagenomic data indicating that there are microbial genes associated with obesity and network-
level differences in microbial metabolic genes between lean and obese persons (Greenblum, et 
al, 2012;  Institute of Medicine (US) Food Forum, 2013; Turnbaugh, et al, 2009; Turnbaugh, et 
al, 2010). We have even discovered specific gut microbes that are associated with more obese or 
leaner individuals, e.g. Christensenella and Akkermansia (Beaumont, et al, 2016; Goodrich, et al, 
2014; Ley, et al, 2006). In fact, there are animal experiments demonstrating that a fecal 
microbiota transplant from an obese animal to a lean animal will cause the lean animal to 
become obese (Backhed, et al, 2004). This phenomenon has caused researcher clinicians to begin 






 Around 60% of human pathogens have zoonotic (mostly livestock) origins (Wardeh, et 
al, 2015). It is not a far reach to think that gut bacteria are similarly transferrable between 
animals and humans. In fact, there are studies confirming this idea and demonstrate that 
domesticated animals and humans share gut microbes with one another (Xiao, et al, 2016; Song, 
et al, 2013). We also have several mechanisms through which livestock gut microbiota can be 
transferred to humans. Raw cattle manure is frequently spread over fields harvested for human 
food. U.S. livestock animals alone produce 2 billion tons of manure per year, management of 
which is variably regulated state by state (Main, 2015). Many farms reuse animal feces as 
components of feed for their livestock as well. Cattle gut microbes are found in food consumed 
by humans (e.g. as seen in outbreaks of Escherichia coli). The classic One Health example 
follows: Cows may graze in a pasture next to a lettuce farm. Cattle may have guts populated by 
E. coli but remain asymptomatic. E. coli can be found present in their feces and their manure 
may contaminate the nearby lettuce field. Humans may then eat the contaminated lettuce and 
become infected with E. coli resulting in morbidity. A similar mechanism may be at play for 
obesogenic gut microbes. It is also possible that certain microbes are transmitted through milk as 
well (Funkhouser & Bordenstein, 2013). Further, veterinary antibiotic metabolites associated 
with adiposity have been found in the urine of Chinese school children (Wang, et al, 2016). 
County-level usage of veterinary antibiotics has also been demonstrated to overlay with county-
level obesity in the U.S. (Riley, et al, 2013). Both of these examples further demonstrate 
potential transferrable pathways from livestock to humans in addition to other potential 
obesogens (i.e. substances that cause obesity). Finally, it is quite possible that horizontal gene 
transfer may be occurring between related animal and human gut bacteria, allowing for increased 





 Therefore, there may be hidden harms when a commercially favorable trait such as 
obesity is selected for in livestock. An individual’s genome resides within a hologenome which 
in turn resides within the environmental metagenome (Theis, et al, 2016). Even without selecting 
for an individual’s genome, the genetic milieu a person lives within (i.e. genetic and epigenetic 
effects) could be augmented by selection of the microbiome or environmental metagenome, and 
this selection could impact the individual’s phenotype via transferable mechanisms. If a 
microbial extended phenotype were selected for artificially in an agricultural species which was 
then transferred to humans (e.g. obesity), then the extended phenotype in the human could be 
obscured partially by epistasis and pleiotropy (Voss, 2017). 
C. Brief Ethical Analysis 
 We are ethically obligated to investigate and mitigate harms to human health, and the 
argument supporting this follows. We create obese livestock animals in order to satiate our meat 
consumption desires. This artificial selection for obese livestock animals may be creating obese 
humans indirectly. Obesity is currently an epidemic in the U.S. and is associated with an 
extensive list of serious and debilitating disease conditions. These diseases in turn would be of 
our own making, and disease is a harm. We have an ethical responsibility to appropriately 
address and curtail diseases that cause harm and suffering not only on an individual patient basis, 
but on public health and societal levels as well. Thus, we are ethically obligated to investigate the 
appropriateness of selecting livestock animals for obesity as it relates to human health. 
 This newfound information around the human hologenome and how it interacts with 
livestock animals and the environmental metagenome add another piece of ethical complexity to 
the context. A prima facie ethical argument in environmental and food ethics states that we 





and animal welfare (Pickles, 2017). It helps humans (bioethics) by improving human health 
through decreasing cardiovascular disease, colorectal cancer, obesity, and other health maladies 
associated with meat consumption. It helps the environment (environmental ethics) by reducing 
harmful climate change through decreasing deforestation, reducing methane production, freeing 
land for conservation, decreasing resources required for livestock, etc. It helps animals (animal 
ethics) by reducing cruel living conditions, decreasing slaughtering, freeing area for conservation 
of wild animals, etc. 
The benefits of decreased meat consumption at a societal level are ethically obvious and 
inarguable. However, suppose humans were more inclined to continue their current meat 
consumption habits. It is not a difficult leap to assume that those who advocate for significantly 
decreasing our meat consumption face an incredible amount of inertia. This section will therefore 
examine the ethics of meat production and consumption in the context of the hologenome 
interaction and on the assumption that human behavior regarding meat consumption will not 
change in a meaningful way. Another critical consideration in ethically analyzing this situation is 
that the world is currently experiencing a looming global catastrophe manifested by climate 
change, and livestock animals contribute significantly to that in a detrimental fashion. In fact, 
livestock animals and global meat production has continued to increase rapidly over the past 50 












Figure 8: Global Meat Production 
 
Furthermore, the meat produced for consumption by livestock animals leaves a significantly 
higher greenhouse gas footprint when compared to vegetable-based food options, as shown 





Figure 9: Greenhouse Gas Emissions by Food Type 
 
By creating more metabolically efficient obese livestock animals, one creates animals that are 
less harmful to the environment and climate change. We can decrease livestock impacts on 
climate change by selecting for animals that grow faster and grow larger. The less time to large 
size, the less time there is a strain on the environment. The greater the efficiency ratio of input to 
output, the fewer resources and animals needed for output. Rather than having to feed and care 
for 4 chickens, one can instead raise 1 with the same meat output. This obesity selection 
approach requires less land and resource input as well as limits greenhouse gas emissions 
compared to a lean animal approach, assuming meat consumption rates remain the same (which 
the data suggests is the case). Therefore, the ethical dilemma is that obese animals appear to be a 





yet the process in itself may be creating obese humans prone to serious diseases. We are trading 
one public health issue for another. 
 
V. Application of the Evidence Appraisal & Actionability Tool 
 It is therefore evident that the hologenome-livestock-obesity problem is one that holds 
potentially significant ethical implications. Further, it vividly illustrates a case of radical 
uncertainty, yet we must nevertheless decide how we ought to respond when presented with such 
evidence. To demonstrate the utility of the Evidence Appraisal & Actionability Tool, we can 
apply it to this scenario. First, in assessing the strength of evidence of the problem, there are 
several key knowledge gaps which would require investigation as to whether the proposed 
association is in fact robust. One gap is the demonstration of the transmission of livestock gut 
microbiota to human populations. Though we have tangential evidence of such, as discussed 
through various metabolite surveys and ecologic-level data, there must be more vigorous data to 
confirm this transmission pathway. Another gap is identifying a more robust catalog of 
obesogenic microbes in livestock as well as in humans, and to then confirm if these same 
microbes are capable of zoonotic and/or reverse-zoonotic transmission. It would also be 
worthwhile to demonstrate if horizontal gene transfer between zoonotic gut microbiota would be 
possible and to document whether obesogenic genes were subjected to this transfer. One must 
also consider information regarding the epigenetic interactions between a host’s genome and 
their microbiome to see if obesogenic microbes selectively impact some individuals or 
populations more than others. Much more substantial research must be conducted to confirm the 





them are based upon related or tangential mechanisms but little direct evidence. Thus, the 
strength of evidence is weak. 
 The second step is to determine the magnitude of impact of the hologenome-livestock-
obesity interaction. Given the discussion above, the potential impacts in responding to this are 
substantial. We also have extensive data regarding human obesity and its detrimental health 
effects. However, we are still lacking in knowing just how extensively the gut microbiome 
impacts human obesity. It would be necessary to conduct further studies regarding specific gut 
microbiota species and their obesogenic potential. It would also require an estimation of 
obesogenic gut microbiota on human obesity itself in terms of risk. In addition, one would need 
to know the number of people such gut microbiota would impact, which would necessitate host 
gene-gut microbe gene interaction prevalence and details regarding exposure (e.g. geography, 
intensity, dose-response, population sizes). Without more precise estimates regarding the 
individual-level impact of gut microbiota on obesity and the populations affected, it is difficult to 
accurately assess how impactful it is. However, given that obesity is so widespread and causes 
significant morbidity and mortality, even a small decrease would yield very meaningful results. 
Therefore, the magnitude of impact at this stage is substantial. However, with more information 
it could become moderate or weak. 
 Since at this point the strength of evidence is weak and the magnitude of impact is 
substantial, the recommendation grade is C1. We therefore have a strong impetus for conducting 
more research in the area. However, it is still much too early to seriously consider it in 
discussions about obesity prevention and control in humans. This scenario clearly illustrates a 
case of radical uncertainty with potentially huge impacts. It demonstrates how the Evidence 





information presented to us, recommend obligations as to how we ought to treat such data in our 
decision-making, and even lead us to what our next steps should be. Further refinement of the 
tool might also offer guidance regarding questions such as: if some of the uncertain connections 
are proven what interim next steps might take place; what might it take to move from C1 to B; 
what does the move between grades in terms of research; what action steps might need to take 
place; and what ethical issues or dilemmas might arise related to the next actions steps? 
 
VI. Conclusions 
 The Evidence Appraisal & Actionability Tool itself is a tool of epistemology and 
consequence – it concerns the appraisal of knowledge with varying degrees of certainty in 
addition to potential impacts and actions. Further, it is designed to help an individual or group 
evaluate what kind of situation of uncertainty they are facing. The grading is intended to take this 
one step further to make credence actionable and determine what a person’s ethical responsibility 
is in light of that. Its ethical relevance is derived from an individual or group utilizing the grade 
in some context as a recommendation for how they ought to act when confronted by varying 
degrees of uncertainty, and particularly in cases of radical uncertainty. It offers a framework for 
approaching an ethically responsible deliberative process which may allow for more ethical 
outcomes based upon those judgments. 
One implication of this tool is the resultant ethical impetus for conducting high quality 
research in order to better inform our decisions. Through this ethical analysis and construction of 
a decision-making framework, we reveal something interesting about how research relates to 





than “if we learn new treatment modalities or harmful exposures to avoid, we can benefit more 
people” – instead, it generates an ethical impetus from research’s influence on the certainty of 
our reasons for making decisions with ethical implications. 
A decision that impacts health without sufficient data to inform the reasoning behind that 
decision is reckless and can therefore be unethical. However, we must sometimes make decisions 
with what data we have, even if it is suboptimal in validity, reliability, and generalizability. A 
decision made with greater confidence linking action with intended consequence is more ethical 
than one in which there is a great gamble and uncertainty related to the action and its 
consequences. A decision may produce unintended harmful effects, negligible effects, or 
beneficial effects. Quality research can provide us with greater confidence in our decision-
making. Therefore, there is an ethical impetus to conduct quality research in order to better 
inform our decision-making such that we choose the best, most ethical course of action. 
Future development of the Evidence Appraisal & Actionability Tool might include the 
construction of an ethical checklist such that the tool would become a component of a larger 
toolkit. This ethical checklist could offer aid to guide the deliberation regarding evidence 
appraisal and actionability to more explicitly incorporate discussion of ethical considerations in 
making decisions about what action to take. 
Humans seemingly have an innate drive for knowledge and understanding. We should 
embrace our inquisitive nature in a meaningful way so that we can be more assured in our action-
consequence flow to improve our ethical decision-making. By removing risk, we create a more 
ethically conducive decision-making environment. Yet even within the suboptimal environment 
of radical uncertainty, there is an ethical way to approach and weigh such information – the 
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Symposium; Honolulu, HI. 
 
●   World Health Organization Research      Nov 2016 – Nov 2017 
o An Overview and Analysis of Noncommunicable Disease Research Priorities in the Eastern Mediterranean 
Region 
o Poster Presentation: 
Kobeissi, L, Smith, HJ, & Alwan A. (November 2017). An Overview and Analysis of 
Cardiovascular Disease Research Priorities in the Eastern Mediterranean Region. Poster presented at: 
American Public Health Association Annual Meeting and Exposition; Atlanta, GA. 
 
●   Tulane DeBakey Scholars Program      Aug 2013 – May 2017 
o The Divergence of Personal Freedom and the Public Health Good 
o The DeBakey Scholars Program is aimed at fostering self-directed, life-long learning by 
allowing select students to perform a 4-year longitudinal research project. 
o Poster Presentation: 
Smith, HJ. (February 2017). The Divergence of Personal Freedom and the Public Health Good. 
Poster presented at: Tulane Health Sciences Research Symposium; New Orleans, LA. 
 
●   Tulane Epidemiology Master’s Thesis        Jun 2015 – Apr 2017 
o An Ethical and Epidemiologic Analysis of U.S. Army Tobacco Health Policy 
o Manuscript: 
Smith, HJ and TN Rieder. “The ethical obligations of a military to the health of its 





o Poster Presentation: 
Smith, HJ. (March 2017). An Ethical and Epidemiologic Analysis of U.S. Army Tobacco Health 
Policy. Poster presented at: Tulane Delta Omega Society Poster Symposium; New Orleans, 
LA. 
 
●   Tulane Bioethics Research         Jan 2013 – Mar 2016 
o The Ethical Implications and Religious Significance of Organ Transplantation Payment Systems 
o Peer-Reviewed Publication:  
Smith, HJ. (2016). “The ethical implications and religious significance of organ 
transplantation payment systems.” Medicine, Health Care, and Philosophy. 19(1): 33-44. PMID: 
25772853. 
o Poster Presentation: 
Smith, HJ. (April 2016). The ethical implications and religious significance of organ transplantation 
payment systems. Poster presented at: Tulane Delta Omega Society Poster Symposium; New 
Orleans, LA. 
 
●   Tulane Community Health Research       Sep 2013 – May 2016 
o Student-Faculty-Community Partnership for Low-Cost Primary Care Clinic in New Orleans 
o Poster Presentation: 
Arno, ST, Flowers, TS, Crowther, JE, Ockenfels, B, Roth, A, Smith, HJ, McConville, JB, 
Mohiuddin, A, & Andrews, J. (May 2016). Student-faculty-community partnership for low-cost primary 
care clinic in New Orleans. Poster presented at: Louisiana State University Health Regional 
Research Day; Baton Rouge, LA. 
 
●   Medical Ethics Education Research        Jun 2014 – Dec 2016 
o Defining and Achieving the Goals of Medical Ethics Education 
o Poster Presentation: 
Smith, HJ. (May 2016). Defining and achieving the goals of medical ethics education.  Poster 
presented at: Tulane Health Sciences Teaching Scholars Education Symposium; New 
Orleans, LA. 
 
●   Undergraduate Research        May 2010 – Aug 2011 
o Aerosolization of Bacteria Caused by Pulsatile Lavage Wound Treatment 
▪ Performed bacterial culturing of wound treatment facilities. Conducted on behalf of 
the Infection Control and Epidemiology department for Lee Memorial Health 
System. 
 
●   High School Research         May 2007 – Apr 2009 





▪ Intel International Science and Engineering Fair (2009) 
o Methicillin-Resistant Staphylococcus aureus in Veterinary Personnel and Their Pets 
▪ Young Epidemiology Scholars (YES) Competition – National Finals (2008) 
 
U.S. ARMY EXPERIENCE 
●   General Preventive Medicine Residency, PGY-2 & 3       Jul 2018 – July 2020 
o Uniformed Services University, Bethesda, MD 
●   Certificate in General Preventive Medicine         Jul 2018 – May 2019 
o Uniformed Services University, Bethesda, MD 
●   Certificate in Clinical Tropical Medicine and Travelers’ Health    Feb 2019 – May 2019 
o Uniformed Services University, Bethesda, MD 
●   Transitional Year Internship, PGY-1         Jun 2017 – Jun 2018 
o Tripler Army Medical Center, Honolulu, HI 
●   Combat Casualty Care Course (C4)       Apr 2018 – May 2018 
o Fort Sam Houston, TX 
●   Officer Promotion to Captain                          May 2017 
o National World War II Museum, New Orleans, LA 
●   Internal Medicine Sub-Internship        Oct 2016 – Nov 2016 
o Tripler Army Medical Center, Honolulu, HI 
●   Preventive Medicine Sub-Internship       Aug 2016 – Sep 2016 
o Walter Reed Army Institute of Research, Silver Spring, MD 
o WRAIR-GEIS Operational Clinical Infectious Disease Course (Aug 2016) 
●   Basic Officer Leadership Course (BOLC)          Jun 2014 – Jul 2014 
o Fort Sam Houston, TX 
o U.S. Army Certificate of Achievement (Jul 2014) 
●   Officer Commission as 2nd Lieutenant                Jan 2013 
o New Orleans, LA 
 
PROFESSIONAL ORGANIZATIONS 
●   Member of the American Medical Association (AMA)       2013-Present 





●   Member of the American College of Preventive Medicine (ACPM)     2015-Present 
 
HOBBIES & INTERESTS 
●   Basketball        ●   Pre-Columbian art and archaeology 
●   Philosophy        ●   Green Bay Packers part-owner 
